Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

If all goes well at the FDA, Cal­lid­i­tas could cross the fin­ish line with its in­flam­ma­to­ry kid­ney dis­ease treat­ment Ne­fe­con next month. But Tra­vere Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER